| Reference |
|---|
Sakata J, Tatsumi T, Sugiyama A, Shimizu A, Inagaki Y, Katoh H, et al. Antibody-mimetic drug conjugate with efficient internalization activity using anti-HER2 VHH and duocarmycin. Protein Expr Purif. 2024;214:106375 pubmed publisher |
Park J, Cho Y, Chae J, Lee J, Kang W. Enhancement of in vivo targeting properties of ErbB2 aptamer by chemical modification. PLoS ONE. 2023;18:e0291624 pubmed publisher |
Mez x151 si Csapl xe1 r M, Sz xf6 x151 r x, Vereb G. CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells. Cancers (Basel). 2023;15: pubmed publisher |
Po x17a niak M, x17b ukowska D, G x119 daj A, Krzy x15b cik M, Por x119 bska N, Zakrzewska M, et al. The Significance of Cell Surface N-Glycosylation for Internalization and Potency of Cytotoxic Conjugates Targeting Receptor Tyrosine Kinases. Int J Mol Sci. 2022;23: pubmed publisher |
Hebbar N, Epperly R, Vaidya A, Thanekar U, Moore S, Umeda M, et al. CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. Nat Commun. 2022;13:587 pubmed publisher |
Garousi J, Ding H, von Witting E, Xu T, Vorobyeva A, Oroujeni M, et al. Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics. 2021;13: pubmed publisher |
Stoup N, Liberelle M, Schulz C, Cavdarli S, Vasseur R, Magnez R, et al. The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis. Cancers (Basel). 2021;13: pubmed publisher |
Chidiac R, Abedin M, Macleod G, Yang A, Thibeault P, Blazer L, et al. A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy. EMBO Mol Med. 2021;13:e13977 pubmed publisher |
Ding H, Xu T, Zhang J, Tolmachev V, Oroujeni M, Orlova A, et al. Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. Pharmaceutics. 2021;13: pubmed publisher |
Yuan S, Brooks S, Nguyen A, Lin W, Johnston T, Maynard J, et al. Bioproduced Proteins On Demand (Bio-POD) in hydrogels using Pichia pastoris. Bioact Mater. 2021;6:2390-2399 pubmed publisher |
Xu T, Ding H, Vorobyeva A, Oroujeni M, Orlova A, Tolmachev V, et al. Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. Cancers (Basel). 2020;13: pubmed publisher |
Youness R, Gad A, Sanber K, Ahn Y, Lee G, Khallaf E, et al. Targeting hydrogen sulphide signaling in breast cancer. J Adv Res. 2021;27:177-190 pubmed publisher |
Dengl S, Mayer K, Bormann F, Duerr H, Hoffmann E, Nussbaum B, et al. Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. Nat Commun. 2020;11:4974 pubmed publisher |
Kondo T, Iwatani Y, Matsuoka K, Fujino T, Umemoto S, Yokomaku Y, et al. Antibody-like proteins that capture and neutralize SARS-CoV-2. Sci Adv. 2020;6: pubmed publisher |
Wege A, Kirchhammer N, Kazandjian L, Prassl S, Brandt M, Piendl G, et al. A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM). J Transl Med. 2020;18:316 pubmed publisher |
Hegde M, Joseph S, Pashankar F, Derenzo C, Sanber K, Navai S, et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020;11:3549 pubmed publisher |
Dai Z, Zhang X, Nasertorabi F, Cheng Q, Li J, Katz B, et al. Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. Sci Adv. 2020;6:eaba6752 pubmed publisher |
Crauwels M, Van Vaerenbergh N, Kulaya N, Vincke C, D Huyvetter M, Devoogdt N, et al. Reshaping nanobodies for affinity purification on protein a. N Biotechnol. 2020;57:20-28 pubmed publisher |
Kadonosono T, Yimchuen W, Ota Y, See K, Furuta T, Shiozawa T, et al. Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use. Sci Rep. 2020;10:891 pubmed publisher |
Parker C, Jacobs T, Huckaby J, Harit D, Lai S. Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies. MBio. 2020;11: pubmed publisher |
Liberelle M, Magnez R, Thuru X, Bencheikh Y, Ravez S, Quenon C, et al. MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis. Sci Rep. 2019;9:16678 pubmed publisher |
Medina Echeverz J, Hinterberger M, Testori M, Geiger M, Giessel R, Bathke B, et al. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies. Nat Commun. 2019;10:5041 pubmed publisher |
Ahn S, Li J, Sun C, Gao K, Hirabayashi K, Li H, et al. Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. Cancer Immunol Res. 2019;7:773-783 pubmed publisher |
Tobin S, Wakefield D, Jones V, Liu X, Schmolze D, Jovanovic Talisman T. Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2. Sci Rep. 2018;8:15154 pubmed publisher |
Helsen C, Hammill J, Lau V, Mwawasi K, Afsahi A, Bezverbnaya K, et al. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nat Commun. 2018;9:3049 pubmed publisher |
Pruszyński M, Kang C, Koumarianou E, Vaidyanathan G, Zalutsky M. d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution. Molecules. 2018;23: pubmed publisher |
Kahl M, Settele F, Knick P, Haupts U, Bosse Doenecke E. Mabfilin and Fabfilin - New antibody-scaffold fusion formats for multispecific targeting concepts. Protein Expr Purif. 2018;149:51-65 pubmed publisher |
Tolmachev V, Grönroos T, Yim C, Garousi J, Yue Y, Grimm S, et al. Molecular design of radiocopper-labelled Affibody molecules. Sci Rep. 2018;8:6542 pubmed publisher |
Correa I, Ilieva K, Crescioli S, Lombardi S, Figini M, Cheung A, et al. Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. Front Immunol. 2018;9:493 pubmed publisher |
Nguyen A, Le K, Maynard J. Identification of high affinity HER2 binding antibodies using CHO Fab surface display. Protein Eng Des Sel. 2018;31:91-101 pubmed publisher |
Lee J, Kang H, Bae J, Kim K, Lee K, Lim K, et al. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. MAbs. 2018;10:547-571 pubmed publisher |
Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, et al. Trivalent CAR T-cells Overcome Interpatient Antigenic Variability in Glioblastoma. Neuro Oncol. 2017;: pubmed publisher |
Yun M, Kim D, Lee J, Kim H, Kim H, Pyo A, et al. A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors. Theranostics. 2017;7:2620-2633 pubmed publisher |
Shinozaki N, Hashimoto R, Fukui K, Uchiyama S. Efficient generation of single domain antibodies with high affinities and enhanced thermal stabilities. Sci Rep. 2017;7:5794 pubmed publisher |
Petrović B, Gianni T, Gatta V, Campadelli Fiume G. Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins. PLoS Pathog. 2017;13:e1006352 pubmed publisher |
Tobias J, Jasinska J, Baier K, Kundi M, Ede N, Zielinski C, et al. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. BMC Cancer. 2017;17:118 pubmed publisher |
Leung I, Jarvik N, Sidhu S. A Highly Diverse and Functional Naïve Ubiquitin Variant Library for Generation of Intracellular Affinity Reagents. J Mol Biol. 2017;429:115-127 pubmed publisher |
Dai P, Zhang C, Welborn M, Shepherd J, Zhu T, Van Voorhis T, et al. Salt Effect Accelerates Site-Selective Cysteine Bioconjugation. ACS Cent Sci. 2016;2:637-646 pubmed |
Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai S, et al. Tandem CAR T cells targeting HER2 and IL13R?2 mitigate tumor antigen escape. J Clin Invest. 2016;126:3036-52 pubmed publisher |
Selis F, Focà G, Sandomenico A, Marra C, Di Mauro C, Saccani Jotti G, et al. Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen. Int J Mol Sci. 2016;17:491 pubmed publisher |
Kanojia D, Balyasnikova I, Morshed R, Frank R, Yu D, Zhang L, et al. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. Stem Cells. 2015;33:2985-94 pubmed publisher |
Leung K, Batey S, Rowlands R, Isaac S, Jones P, Drewett V, et al. A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis. Mol Ther. 2015;23:1722-1733 pubmed publisher |
Zhou Q, Uhlig K, Muth A, Kimpel J, Lévy C, Münch R, et al. Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors. J Immunol. 2015;195:2493-501 pubmed publisher |
Vanseggelen H, Hammill J, Dvorkin Gheva A, Tantalo D, Kwiecien J, Denisova G, et al. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. Mol Ther. 2015;23:1600-10 pubmed publisher |
Lin C, Pan I, Li Y, Pan Y, Lin M, Lu Y, et al. The adjuvant effects of high-molecule-weight polysaccharides purified from Antrodia cinnamomea on dendritic cell function and DNA vaccines. PLoS ONE. 2015;10:e0116191 pubmed publisher |
Liu Z, Leng E, Gunasekaran K, Pentony M, Shen M, Howard M, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem. 2015;290:7535-62 pubmed publisher |
Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23:330-8 pubmed publisher |
Nilvebrant J, Astrand M, Georgieva Kotseva M, Björnmalm M, Löfblom J, Hober S. Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin. PLoS ONE. 2014;9:e103094 pubmed publisher |
Hussain S, Rodriguez Fernandez M, Braun G, Doyle F, Ruoslahti E. Quantity and accessibility for specific targeting of receptors in tumours. Sci Rep. 2014;4:5232 pubmed publisher |
Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M, et al. Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities. PLoS ONE. 2014;9:e97292 pubmed publisher |
Kang J, Poovassery J, Bansal P, You S, Manjarres I, Ober R, et al. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. MAbs. 2014;6:340-53 pubmed publisher |
Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013;21:2087-101 pubmed publisher |
Frese K, Eisenmann M, Ostendorp R, Brocks B, Pabst S. An automated immunoassay for early specificity profiling of antibodies. MAbs. 2013;5:279-87 pubmed publisher |
Axup J, Bajjuri K, Ritland M, Hutchins B, Kim C, Kazane S, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012;109:16101-6 pubmed publisher |
Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjöberg A, Larsson B, et al. Design of an optimized scaffold for affibody molecules. J Mol Biol. 2010;398:232-47 pubmed publisher |
Serpe M, Umulis D, Ralston A, Chen J, Olson D, Avanesov A, et al. The BMP-binding protein Crossveinless 2 is a short-range, concentration-dependent, biphasic modulator of BMP signaling in Drosophila. Dev Cell. 2008;14:940-53 pubmed publisher |
Gonzalez R, Seurynck Servoss S, Crowley S, Brown M, Omenn G, Hayes D, et al. Development and validation of sandwich ELISA microarrays with minimal assay interference. J Proteome Res. 2008;7:2406-14 pubmed publisher |
Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels W, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007;67:5957-64 pubmed |
